Model Systems Core (Mayo Clinic Pirnie Translational Polycystic Kidney Disease Center)

Preclinical Trials Requests

The Mayo Clinic Pirnie Translational Polycystic Kidney Disease Center has long-standing expertise in conducting rodent preclinical trials (more than 30 in the last five years), which includes utilization and expertise in a range of rodent PKD models (hypomorphic and conditional), dosing regimens, drug delivery methods, phenotypic characterization, and statistical analysis. We also have ample expertise in testing compounds of interests in in vivo nematode and zebrafish models, in vitro cellular models, and ex vivo metanephric culture systems, all of which are more cost, space and time efficient, allowing relatively higher throughput screening of small molecules and potential therapeutics.

Given our extensive expertise, the Model Systems Core offers help to other researchers with preclinical trials needs.

Complete the online form to help us gain a better understanding of your interests and needs. After we review your request, we'll respond to inquiries within a week or so and initiate a teleconference to discuss the request.

Use this form to submit your request online.

Note: This form is not for patient use and should not be used to share any kind of patient information. Information you provide is used only to address your inquiry and not shared outside Mayo Clinic. Communication by email is not secure.

Your information

Enter your information. All fields are required, unless indicated as optional.

Name:

Name is required.Name is required.

*

Title:

Title is required.Title is required.

*

Organization name:

Organization name is required.Organization name is required.

*

Organization type:

Academic Industry

*

Contact email:

E-mail is required.

*

Contact phone:

Phone is required.

*

For more information about rodent models and an example of their application in autosomal dominant polycystic kidney disease (ADPKD) preclinical trials, see the related publications.

Select your models of interest

C. elegans

Zebrafish

Metanephric organ culture [1]

Pkd1RC/RC mice [2]

Pkd1fl/fl conditional knockout mice [3]

pck rat [4]

Other

*

If other, specify (optional):

If other, specify (optional): must have at least 0 and no more than 256 characters.The value of the If other, specify (optional): field is not valid.

Compound information

Specify characteristics of your compound (dosage, administration route and frequency, toxicity, targeted pathway, or others.):

Compound characteristics are required.Compound characteristics are required.

*

Request tolvaptan as a positive control

Yes No

*

Other information (optional):

Other information (optional): must have at least 0 and no more than 512 characters.The value of the Other information (optional): field is not valid.

Select your tests of interest

Renal morphology (ultrasound scanning, MRI, histochemistry, and others.)

Molecular signaling pathways (cAMP, mTOR, ERK, and others.)

Blood test

Urine test

Renal function test

Other

*

If other, specify (optional):

If other, specify (optional): must have at least 0 and no more than 256 characters.The value of the If other, specify (optional): field is not valid.

Questions or comments

Questions or comments must have at least 0 and no more than 512 characters.The value of the Questions or comments field is not valid.

Important: After submission, do not leave this form until you see the confirmation message.

Mayo Clinic Number

Your Mayo Clinic number is a 7, 8 or 9-digit number we assign to you as a new patient prior to your first visit. You can find it near the top of a range of documents, including pre-visit questionnaires, clinical notes, care summaries, and correspondence.

If you do have Mayo paperwork handy, it's often quickest simply to look for it there. Scroll down to see some examples of how the number shows up:

In correspondence:

In pre-appointment questionnaires

In medical documents:

In dismissal summaries:

In several other kinds of documents:

Related publications

1. Magenheimer BS, St John PL, Isom KS, Abrahamson DR, C De Lisle RC, Wallace DP, Maser RL, Grantham JJ, Calvet JP. Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to cAMP stimulation with cystic fibrosis transmembrane conductance regulator/Na(+),K(+),2Cl(-) Co-transporter-dependent cystic dilation. Journal of the American Society of Nephrology. 2006; doi:10.1681/ASN.2006030295.
2. Hopp K, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE. Tolvaptan plus Pasireotide Shows Enhanced Efficacy in a PKD1 Model. Journal of the American Society of Nephrology. 2015; doi:10.1681/ASN.2013121312.
3. Chen L, Zhou X, Fan LX, Yao Y, Swenson-Fields KI, Gadjeva M, Wallace DP, Peters DJM, Yu A, Grantham JJ, Li X. Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease. The Journal of Clinical Investigation. 2015; doi:10.1172/JCI80467.
4. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. Journal of the American Society of Nephrology. 2008; doi:10.1681/ASN.2007060688.